Premium
Use of radiation therapy in posttransplant lymphoproliferative disorder (PTLD) after liver transplantation
Author(s) -
Koffman B.H.,
Kennedy A.S.,
Heyman M.,
Colonna J.,
Howell C.
Publication year - 2000
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(20000420)90:2<104::aid-ijc6>3.0.co;2-0
Subject(s) - immunosuppression , medicine , lymphoproliferative disorders , radiation therapy , porta hepatis , post transplant lymphoproliferative disorder , complication , lymphoproliferative disease , liver transplantation , radiology , transplantation , surgery , pathology , lymphoma , rituximab
Posttransplant lymphoproliferative disorder (PTLD) is a common and life‐threatening complication of immunosuppression used to prevent rejection of solid organ and bone marrow transplants. There is no standardized treatment algorithm, but numerous management strategies are available. We describe a patient who developed a solitary lymphoproliferative lesion in the porta hepatis 9 months after orthotopic liver transplant. Following reduction in immunosuppression with no response, she was treated with involved field radiotherapy utilizing CT‐based treatment planning. A partial radiographic response was obtained, and she has not developed disease in the engrafted liver or systemically. Based on the present case report, involved field radiotherapy seems to be a reasonable treatment option for patients with localized PTLD. Int. J. Cancer (Radiat. Oncol. Invest.) 90:104–109, 2000. © 2000 Wiley‐Liss, Inc.